Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019



Amit Nathwani

Amit Nathwani

CSO, Freeline Therapeutics

Professor Amit Nathwani, a NIHR Senior Investigator, is the Director of the Katharine Dormandy Haemophilia Centre at the Royal Free Hospital and Professor of Haematology at UCL. He is internationally recognised for his pioneering work in gene therapy and is the recipient of the ESGCT Outstanding Achievement Award and the Human Gene Therapy Award amongst others. Prof Nathwani developed a novel gene transfer approach that enabled the first successful trial of gene therapy in a bleeding disorder- haemophilia B and this has now become the platform for a variety of genetic disorders. He has also developed a novel approach for gene therapy of haemophilia A that has resulted in normalisation of coagulation factor VIII levels and correction of bleeding diathesis in severely affected patients. His group is working on other translational gene transfer approaches for a range of monogenetic disorders as well as malignancies.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd